EMT has been observed in tumor samples from patients with non-small cell lung cancer (NSCLC) that developed resistance to epidermal growth factor receptor inhibitors (31, 32), and with pancreatic cancer that developed resistance to gemcitabine (33). This evidence concerns the gene EGFR and neoplasm.